8-Hydroxy-2-Deoxyguanosine Levels and Cardiovascular Disease: A Systematic Review and Meta-Analysis of the Literature

Alessandro Di Minno, Linda Turnu, Benedetta Porro, Isabella Squellerio, Viviana Cavalca, Elena Tremoli, Matteo Nicola Dario Di Minno, Alessandro Di Minno, Linda Turnu, Benedetta Porro, Isabella Squellerio, Viviana Cavalca, Elena Tremoli, Matteo Nicola Dario Di Minno

Abstract

Significance: 8-Hydroxy-2-deoxyguanosine (8-OHdG) is generated after the repair of ROS-mediated DNA damages and, thus, is one of the most widely recognized biomarkers of oxidative damage of DNA because guanosine is the most oxidized among the DNA nucleobases. In several pathological conditions, high urinary levels of oxidized DNA-derived metabolites have been reported (e.g., cancer, atherosclerosis, hypertension, and diabetes).

Recent advances: Even if published studies have shown that DNA damage is significantly associated with the development of atherosclerosis, the exact role of this damage in the onset and progression of this pathology is not fully understood, and the association of oxidative damage to DNA with cardiovascular disease (CVD) still needs to be more extensively investigated. We performed a meta-analysis of the literature to investigate the association among 8-OHdG levels and CVD.

Critical issues: Fourteen studies (810 CVD patients and 1106 controls) were included in the analysis. We found that CVD patients showed higher 8-OHdG levels than controls (SMD: 1.04, 95%CI: 0.61, 1.47, p < 0.001, I(2) = 94%, p < 0.001). The difference was confirmed both in studies in which 8-OHdG levels were assessed in urine (MD: 4.43, 95%CI: 1.71, 7.15, p = 0.001) and in blood samples (MD: 1.42, 95%CI: 0.64, 2.21, p = 0.0004). Meta-regression models showed that age, hypertension, and male gender significantly impacted on the difference in 8-OHdG levels among CVD patients and controls.

Future directions: 8-OHdG levels are higher in patients with CVD than in controls. However, larger prospective studies are needed to test 8-OHdG as a predictor of CVD.

Figures

FIG. 1.
FIG. 1.
8-OHdG levels in CVD patients and controls. 8-OHdG, 8-hydroxy-2-deoxyguanosine; CVD, cardiovascular disease.
FIG. 2.
FIG. 2.
Metaregression analysis. Clinical and demographic characteristics impacting the effect size.

References

    1. Andreassi MG, Botto N, Cocci F, Battaglia D, Antonioli E, Masetti S, Manfredi S, Colombo MG, Biagini A, and Clerico A. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum Genet 112: 171–177, 2003
    1. Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, Kawakami M, and Momomura S. Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J 73: 1523–1530, 2009
    1. Arca M, Conti B, Montali A, Pignatelli P, Campagna F, Barilla F, Tanzilli G, Verna R, Vestri A, Gaudio C, and Violi F. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol 28: 752–757, 2008
    1. Beckman KB. and Ames BN. Oxidative decay of DNA. J Biol Chem 272: 19633–19636, 1997
    1. Brea D, Roquer J, Serena J, Segura T, and Castillo J. Oxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins. BMC Neurol 12: 65, 2012
    1. Duval S. and Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455–463, 2000
    1. Edwards KD. and Whyte HM. Creatinine excretion and body composition. Clin Sci 18: 361–366, 1959
    1. Evans MD, Dizdaroglu M, and Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 567: 1–61, 2004
    1. Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T 33: 700–711, 2008
    1. Gackowski D, Kruszewski M, Jawien A, Ciecierski M, and Olinski R. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med 31: 542–547, 2001
    1. Gorbunova V, Seluanov A, Mao Z, and Hine C. Changes in DNA repair during aging. Nucleic Acids Res 35: 7466–7474, 2007
    1. Higgins JP, Thompson SG, Deeks JJ, and Altman DG. Measuring inconsistency in meta-analyses. BMJ 327: 557–560, 2003
    1. Himmetoglu S, Dincer Y, Bozcali E, Ali Vural V, and Akcay T. Oxidative DNA damage and antioxidant defense after reperfusion in acute myocardial infarction. J Investig Med 57: 595–599, 2009
    1. Ho HY, Cheng ML, Chen CM, Gu PW, Wang YL, Li JM, and Chiu DT. Oxidative damage markers and antioxidants in patients with acute myocardial infarction and their clinical significance. Biofactors 34: 135–145, 2008
    1. Idei N, Nishioka K, Soga J, Hidaka T, Hata T, Fujii Y, Fujimura N, Maruhashi T, Mikami S, Teragawa H, Kihara Y, Noma K, Chayama K, and Higashi Y. Vascular function and circulating progenitor cells in thromboangitis obliterans (Buerger's disease) and atherosclerosis obliterans. Hypertension 57: 70–78, 2011
    1. Jaruga P, Rozalski R, Jawien A, Migdalski A, Olinski R, and Dizdaroglu M. DNA damage products (5′R)- and (5′S)-8,5′-cyclo-2′-deoxyadenosines as potential biomarkers in human urine for atherosclerosis. Biochemistry 51: 1822–1824, 2012
    1. Juni P, Witschi A, Bloch R, and Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282: 1054–1060, 1999
    1. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 387: 147–163, 1997
    1. Kaya Y, Cebi A, Soylemez N, Demir H, Alp HH, and Bakan E. Correlations between oxidative DNA damage, oxidative stress and coenzyme Q10 in patients with coronary artery disease. Int J Med Sci 9: 621–626, 2012
    1. Keaney JF, Jr., Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, and Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434–439, 2003
    1. Kim JY, Lee JW, Youn YJ, Ahn MS, Ahn SG, Yoo BS, Lee SH, Yoon J, and Choe KH. Urinary levels of 8-iso-prostaglandin f2alpha and 8-hydroxydeoxyguanine as markers of oxidative stress in patients with coronary artery disease. Korean Circ J 42: 614–617, 2012
    1. Kroese LJ. and Scheffer PG. 8-Hydroxy-2′-deoxyguanosine and cardiovascular disease: a systematic review. Curr Atheroscler Rep 16: 452, 2014
    1. Lai CQ, Tucker KL, Parnell LD, Adiconis X, Garcia-Bailo B, Griffith J, Meydani M, and Ordovas JM. PPARGC1A variation associated with DNA damage, diabetes, and cardiovascular diseases: the Boston Puerto Rican Health Study. Diabetes 57: 809–816, 2008
    1. Lin HJ, Chen ST, Wu HY, Hsu HC, Chen MF, Lee YT, Wu KY, and Chien KL. Urinary biomarkers of oxidative and nitrosative stress and the risk for incident stroke: a nested case-control study from a community-based cohort. Int J Cardiol 183: 214–220, 2015
    1. Loffredo L, Pignatelli P, Cangemi R, Andreozzi P, Panico MA, Meloni V, and Violi F. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc Surg 44: 525–530, 2006
    1. Mendes B, Silva P, Mendonca I, Pereira J, and Camara JS. A new and fast methodology to assess oxidative damage in cardiovascular diseases risk development through eVol-MEPS-UHPLC analysis of four urinary biomarkers. Talanta 116: 164–172, 2013
    1. Moher D, Liberati A, Tetzlaff J, and Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097, 2009
    1. Nagayoshi Y, Kawano H, Hokamaki J, Miyamoto S, Kojima S, Shimomura H, Tsujita K, Sakamoto T, Yoshimura M, and Ogawa H. Urinary 8-hydroxy-2′-deoxyguanosine levels increase after reperfusion in acute myocardial infarction and may predict subsequent cardiac events. Am J Cardiol 95: 514–517, 2005
    1. Nagayoshi Y, Kawano H, Hokamaki J, Uemura T, Soejima H, Kaikita K, Sugiyama S, Yamabe H, Shioji I, Sasaki S, Kuroda Y, and Ogawa H. Differences in oxidative stress markers based on the aetiology of heart failure: comparison of oxidative stress in patients with and without coronary artery disease. Free Radic Res 43: 1159–1166, 2009
    1. Najar RA, Ghaderian SMH, Vakili H, Panah AST, Farimani AR, Rezaie G, and Harchegani AB. The role of p53, bax, bcl2, and 8-OHdG in human acute myocardial infarction. Cent Eur J Biol 5: 439–445, 2010
    1. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, and Saez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41: 1096–1101, 2003
    1. Romer W, Oettel M, Menzenbach B, Droescher P, and Schwarz S. Novel estrogens and their radical scavenging effects, iron-chelating, and total antioxidative activities: 17 alpha-substituted analogs of delta 9(11)-dehydro-17 beta-estradiol. Steroids 62: 688–694, 1997
    1. Rosello-Lleti E, de Burgos FG, Morillas P, Cortes R, Martinez-Dolz L, Almenar L, Grigorian L, Orosa P, Portoles M, Bertomeu V, and Rivera M. Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension. Am J Hypertens 25: 236–242, 2012
    1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115–126, 1999
    1. Rozalski R, Migdalski A, Gackowski D, Guz J, Siomek A, Foksinski M, Szpila A, Zarakowska E, Majer M, Jawien A, and Olinski R. Does morphology of carotid plaque depend on patient's oxidative stress? Clin Biochem 46: 1030–1035, 2013
    1. Serdar M, Sertoglu E, Uyanik M, Tapan S, Akin K, Bilgi C, and Kurt I. Comparison of 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy. Free Radic Res 46: 1291–1295, 2012
    1. Shi GX, Liu CZ, Wang LP, Guan LP, and Li SQ. Biomarkers of oxidative stress in vascular dementia patients. Can J Neurol Sci 39: 65–68, 2012
    1. Shigenaga MK, Gimeno CJ, and Ames BN. Urinary 8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci U S A 86: 9697–9701, 1989
    1. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 91: 31S–38S, 1991
    1. Simic MG. Urinary biomarkers and the rate of DNA damage in carcinogenesis and anticarcinogenesis. Mutat Res 267: 277–290, 1992
    1. Sterne JA, Egger M, and Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101–105, 2001
    1. Tang M. and Subbiah MT. Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. Biochim Biophys Acta 1299: 155–159, 1996
    1. Topic A, Francuski D, Markovic B, Stankovic M, Dobrivojevic S, Drca S, and Radojkovic D. Gender-related reference intervals of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine determined by liquid chromatography-tandem mass spectrometry in Serbian population. Clin Biochem 46: 321–326, 2013
    1. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44–84, 2007
    1. Wang Y, Yu Q, Chen Y, and Cao F. Pathophysiology and therapeutics of cardiovascular disease in metabolic syndrome. Curr Pharm Des 19: 4799–4805, 2013
    1. Xiang F, Shuanglun X, Jingfeng W, Ruqiong N, Yuan Z, Yongqing L, and Jun Z. Association of serum 8-hydroxy-2′-deoxyguanosine levels with the presence and severity of coronary artery disease. Coron Artery Dis 22: 223–227, 2011
    1. Yin B, Whyatt RM, Perera FP, Randall MC, Cooper TB, and Santella RM. Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA. Free Radic Biol Med 18: 1023–1032, 1995

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する